Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC 50 =9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (K D(app) of 0.46 μM).
性状
Solid
IC50 & Target[1][2]
TAK1 9.5 nM (IC50) IRAK4 120 nM (IC50
体外研究(In Vitro)
Takinib (10-10000 nM; 24 hours) induces apoptosis following TNF-α stimulation in MDA-MB-231 cells.Takinib (10 μM; 0-1 hours) reduces phosphorylation of IKK and p65.Takinib serves as a chemical starting point for the development of Pf PK9 (KD(app) of 0.46 μM) inhibitors for malaria.Takinib (2 hours; 0.1-20 μM; human RASFs) induces phosphorylation of TAK1, STAT3 and STAT3 in IL-1β-treated (10 ng/mL; 30 min) RASFs. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Takinib (50 mg/kg; intraperitoneally; daily from days 18-36) reduces the clinical score in type II collagen-induced arthritis (CIA) mouse model of rheumatoid arthritis.
Takinib (50 mg/kg; oral gavage; daily until 17 days) slows tumor growth in the Hodgkin lymphoma xenograft NSG mice. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Totzke J, et al. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chem Biol. 2017 Aug 17;24(8):1029-1039.[2]. Scarneo SA, et.al. Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis Res Ther. 2019 Dec 17;21(1):292.
溶解度数据
In Vitro: DMSO : 50 mg/mL (155.11 mM; Need ultrasonic)配制储备液
[1]. Totzke J, et al. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chem Biol. 2017 Aug 17;24(8):1029-1039.[2]. Scarneo SA, et.al. Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis Res Ther. 2019 Dec 17;21(1):292.